PPB - Services

Complaints, Feedback and Enquiry

๐„๐ง๐ก๐š๐ง๐œ๐ข๐ง๐  ๐Ž๐ฏ๐ž๐ซ๐ฌ๐ข๐ ๐ก๐ญ ๐จ๐Ÿ ๐‹๐จ๐œ๐š๐ฅ ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ ๐Œ๐š๐ง๐ฎ๐Ÿ๐š๐œ๐ญ๐ฎ๐ซ๐ž๐ซ๐ฌ: ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ฒ ๐š๐ง๐ ๐๐จ๐ข๐ฌ๐จ๐ง๐ฌ ๐๐จ๐š๐ซ๐ ๐ˆ๐ง๐ข๐ญ๐ข๐š๐ญ๐ž๐ฌ ๐’๐ญ๐ซ๐š๐ญ๐ž๐ ๐ข๐œ ๐Œ๐ž๐ž๐ญ๐ข๐ง๐  – 27th February 2024

Nairobi, Kenya – Today, the Pharmacy and Poisons Board (PPB) convened a meeting with top management from local pharmaceutical manufacturing companies to discuss strategies for enhancing oversight of local manufacturers.

The meeting highlighted the importance of implementing a rapid alert system to manage substandard and falsified medicines, as well as the application of a mandatory bioequivalence roadmap for eligible products.

Dr. Ahmed Mohamed, Director of Health Products and Technologies, representing PPB’s Chief Executive Officer, Dr. F. M. Siyoi, emphasized the need for enforcing regulatory instruments and taking prompt regulatory actions in cases of noncompliance that pose risks to the quality, safety, and efficacy of health products.

He expressed gratitude to participants for their collaborative efforts as PPB works towards achieving World Health Organization Maturity Level 3.


Public Relations

Leave a comment

Your email address will not be published. Required fields are marked *